Navigation Links
Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
Date:10/21/2013

ROCKVILLE, Md., Oct. 21, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).  The study was led by Dr. Jennifer R. Diamond of University of Colorado and the results were presented at the AACR-NCI-EORTC International Conference being held this week in Boston, Massachusetts.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

Dr. Diamond commented, "The purpose of this study is to utilize TNBC cell line gene knockdown models to investigate further the role of p53 and p73 in mediating sensitivity to ENMD-2076.  Data from the study demonstrate that ENMD-2076 exhibited robust anticancer activity in both p53 mutated and p53 wild type (WT) cell lines. The data also illustrate that both p53 and p73 mediate sensitivity to ENMD-2076 in p53 WT TNBC, while p73 is essential for induction of senescence following exposure to ENMD-2076, providing support on the development of predictive biomarkers of response to ENMD-2076 in p53 mutated TNBC currently underway."

Ken K. Ren, Ph.D, EntreMed's Chief Executive Officer, commented, "ENMD-2076 is currently in Phase 2 clinical trials in patients with TNBC and advanced/metastatic soft tissue sarcoma, and we expect to begin enrolling in a multi-center Phase 2 trial in ovarian clear cell carcinomas. We have also been conducting additional preclinical studies on the drug candidate primarily to support our clinical trials with better understanding of its mechanism of actions, predictive biomarkers, and scientific rationale for new
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
2. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
3. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
4. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
5. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
6. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
8. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
11. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, received official notification from the European Patent ... key patent supporting its iSONEP™ and ASONEP™ programs. ... patent No. 2087002, claims compositions of matter related ... lead compounds, iSONEP and ASONEP. Sonepcizumab is an ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis ... Foundation (HNF), both philanthropies, announced today the creation ... for the treatment of the rare disease known ... Alliance announced its alliance model earlier this month. ... demonstration of a collaborative model where researchers and ...
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... Reportlinker.com announces that a new market research report ... Probiotics and Prebiotics in Clinical Nutrition ... Overall sales of clinical nutrition products are ... EU as well as rising incidence of illnesses and ...
... NEW YORK, May 3, 2011 Reportlinker.com announces that ... catalogue: Cancer Reports Bundle ... Bundle includes the following TriMark Publications reports at a 15% ... - Biomarker Technology Platforms for Cancer Diagnoses and Therapies. ...
Cached Medicine Technology:Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 3Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 4Reportlinker Adds Cancer Reports Bundle 2Reportlinker Adds Cancer Reports Bundle 3Reportlinker Adds Cancer Reports Bundle 4Reportlinker Adds Cancer Reports Bundle 5Reportlinker Adds Cancer Reports Bundle 6Reportlinker Adds Cancer Reports Bundle 7Reportlinker Adds Cancer Reports Bundle 8
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... and is performed without anesthesia , , WEDNESDAY, Oct. 3 ... of an innovative form of colonoscopy that relies on ... , When it comes to detecting polyps that ... as effective as the traditional approach of using a ...
... It cuts rates of hospitalizations and deaths, study finds, , , WEDNESDAY, ... an annual flu shot will reduce the risk you,ll be hospitalized ... flu-related death by 48 percent. , That,s the conclusion of new ... England Journal of Medicine . , "This is a bad disease ...
... Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ABAX ... analysis systems, announced today the launch of the ... the Piccolo xpress(TM) point of,care analyzer. The ... imaging and,radiology centers in the United States to ...
... Acceptance of Umbilical Cord Blood Stem Cells as a Curative ... ... Inc. has been named,to Deloitte,s prestigious Technology Fast 50 Program for ... life sciences companies in the area by Deloitte & Touche USA ...
... CHICAGO, Oct. 3 President Bush,s veto today,of ... for millions of,children from families with low incomes ... dental health, says Oral Health America, a national,advocacy ... ten million children eligible for coverage through a,bipartisan, ...
... regarded as a barometer of a populations general health ... rate in 2006 was 5.9 infant deaths for every 1,000 ... made major progress in reducing infant deaths since the early ... but the decline has leveled off in recent years. The ...
Cached Medicine News:Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Flu Vaccine Does Protect Older People 2Health News:Flu Vaccine Does Protect Older People 3Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 2Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 4Health News:SCHIP Veto a Big Cavity for Children's Oral Healthcare, Advocates Say 2Health News:New York City's infant mortality rate declined in 2006 2Health News:New York City's infant mortality rate declined in 2006 3Health News:New York City's infant mortality rate declined in 2006 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: